Skip to main navigation Skip to search Skip to main content

Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases

  • Negin Yavari
  • , Hashem Ghoraba
  • , Christopher Or
  • , Zheng Xian Thng
  • , S. Saeed Mohammadi
  • , Irmak Karaca
  • , Azadeh Mobasserian
  • , Amir Akhavanrezayat
  • , Anthony Le
  • , Xun Lyu
  • , Anadi Khatri
  • , Woong Sun Yoo
  • , Dalia El Feky
  • , Ngoc Trong Tuong Than
  • , Osama Elaraby
  • , Aim On Saengsirinavin
  • , Xiaoyan Zhang
  • , Frances Andrea Anover
  • , Ankur Sudhir Gupta
  • , Muhammad Sohail Halim
  • Louis A. Jison, Quan Dong Nguyen

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Repository corticotropin injection (RCI) has been suggested to exert immunomodulatory and anti-inflammatory effects in ocular inflammation. The index retrospective study aimed to evaluate the efficacy and tolerability of subcutaneous RCI in patients with active scleritis or uveitis. Main body: Medical records of patients who were diagnosed with different types of active scleritis or uveitis and received RCI for more than six months at a tertiary eye center were reviewed. Patient characteristics including age, sex, comorbidities, clinical findings, treatment details, and adverse events were recorded. A total of 17 eyes of 17 patients were included. Median age was 43 years old and 53% of patients were male. Mean treatment duration was 25.4 ± 15.5 months. Indications for RCI therapy were scleritis (7 anterior and 1 posterior) (47.8%), panuveitis (17.4%), retinal vasculitis (17.4%), chronic/recurrent anterior uveitis (13%), and posterior uveitis (4.35%). RCI was initiated at a dose of 40 to 80 units 3 times weekly. Given the adequate control of inflammation, RCI was successfully discontinued in four patients (23.5%). Prior to RCI therapy, 14 (82.3%) patients were on oral prednisone at an average of 10 mg daily (range 2.5–40 mg), and two (11.7%) patients discontinued prednisone immediately before initiating RCI due to side effects. After six months of therapy, the prednisone dose was reduced in four (23.5%) patients to an average of 3 mg daily (range 1–5 mg) and was stopped in eight (53%) patients. Concomitant immunomodulatory therapies (IMTs) included mycophenolate mofetil (23.5%) and methotrexate (23.5%), and adalimumab (23.5%). Ten patients were on IMTs prior to using RCI, and during the course of treatment, IMT was stopped in two patients and reduced in one. Side effects included insomnia (23%), hypertension (11.7%), lower extremity edema (11.7%), hyperglycemia (11.7%), weight gain (11.7%), and infection (5.8%). Conclusion: RCI may be considered as a potential therapy with acceptable tolerability for patients with non-infectious scleritis or uveitis.

Original languageEnglish (US)
Article number56
JournalJournal of Ophthalmic Inflammation and Infection
Volume14
Issue number1
DOIs
StatePublished - Dec 2024
Externally publishedYes

Keywords

  • Adrenocorticotropic hormone
  • Repository corticotropin injection
  • Scleritis
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases'. Together they form a unique fingerprint.

Cite this